Optician's warning to 'stop habit' or risk 'silent killer' that is on rise
With February marking Age-related Macular Degeneration (AMD) Awareness Month 2025 in the UK, recent NHS statistics have shown ...
Managed Healthcare Executive20h
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
Pharmaceutical Technology57m
Astellas seeks conditional approval for GA treatment in Japan
Astellas Pharma has submitted an NDA to Japan's Ministry of Health, Labour and Welfare seeking conditional approval of ACP.
Daily1h
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
pharmaphorum2h
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) ...
ophthalmologytimes22h
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Pharm Exec19h
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
The Pharma Letter4h
Astellas submits NDA for avacincaptad pegol in Japan
Japanese drugmaker Astellas Pharma says it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor ...
Business Wire19h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...